Education
About Us
Working with TipRanks
Follow Us
Zevra Therapeutics, Inc. (ZVRA)
:ZVRA
Earnings Data
Report Date
Aug 19, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.09Last Year’s EPS
-0.48Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: 3.43%
|Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong performance and strategic progress, especially with the successful launch of MIPLYFFA and robust financial positioning. However, challenges remain with OLPRUVA's market penetration and limited initial market access for MIPLYFFA.Company Guidance
During Zevra's First Quarter 2025 Financial Results and Corporate Update Conference Call, the company provided various metrics reflecting its strategic progress. Zevra announced that for its newly launched product MIPLYFFA, aimed at Niemann-Pick disease type C (NPC), it had received 122 prescription enrollment forms by March 31, 2025, with 13 forms in the first quarter alone. Approximately 38% of covered lives have been secured for MIPLYFFA, aligning with the company's expectations at this stage. Additionally, Zevra's other product, OLPRUVA, received a total of 28 prescription enrollment forms since its promotion began in January 2024, including 5 forms in the first quarter of 2025. Financially, Zevra reported a net revenue of $20.4 million for Q1 2025, with $17.1 million attributed to MIPLYFFA. The company's strategic focus includes advancing their Phase 3 Discover trial for Celiprolol and aiming to extend MIPLYFFA's availability beyond the U.S., with an MAA submission planned in Europe, where approximately 1,100 people are estimated to be living with NPC.Successful Launch of MIPLYFFA
Exceeded internal expectations for MIPLYFFA with over one-third of diagnosed Niemann-Pick disease type C (NPC) patients in the U.S. enrolled. Received 122 prescription enrollment forms by March 31, 2025, with 13 in Q1 2025.
Expansion Plans for MIPLYFFA
Plans to expand availability of MIPLYFFA outside the U.S. with a marketing authorization application in Europe in the second half of 2025, targeting approximately 1100 people living with NPC.
Financial Strength and Flexibility
Monetization of pediatric rare disease priority review voucher added $148.3 million of non-dilutive capital to the balance sheet, increasing total cash, cash equivalents, and investments to $217 million.
Recognition of Innovation
Earned a spot on Fast Company's top 10 most innovative companies list in the medicines, therapeutics, and pharmaceuticals category.
Pipeline Progress with Celiprolol
Phase 3 Discover trial for Celiprolol continues to progress with 32 patients enrolled for vascular Ehlers-Danlos syndrome (VEDS).
---
ZVRA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ZVRA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | $7.87 | $8.14 | +3.43% |
Mar 11, 2025 | $8.07 | $7.92 | -1.86% |
Nov 12, 2024 | $8.57 | $8.66 | +1.05% |
Aug 13, 2024 | $6.78 | $6.99 | +3.10% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Zevra Therapeutics, Inc. (ZVRA) report earnings?
Zevra Therapeutics, Inc. (ZVRA) is schdueled to report earning on Aug 19, 2025, TBA Not Confirmed.
What is Zevra Therapeutics, Inc. (ZVRA) earnings time?
Zevra Therapeutics, Inc. (ZVRA) earnings time is at Aug 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ZVRA EPS forecast?
ZVRA EPS forecast for the fiscal quarter 2025 (Q2) is -0.09.
---